Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?

被引：36

作者：

Chavda, Vivek P. ^{[1
]}

Apostolopoulos, Vasso ^{[2
,3
]}

机构：

[1] LM Coll Pharm, Dept Pharmaceut & Pharmaceut Technol, Ahmadabad 380008, Gujarat, India

[2] Victoria Univ, Inst Hlth & Sport, Melbourne, Vic 3030, Australia

[3] Australian Inst Musculoskeletal Sci AIMSS, Immunol Program, Melbourne, Vic 3021, Australia

来源：

VACCINES | 2022年 / 10卷 / 03期

关键词：

Omicron variant; SARS-CoV-2; booster dose; vaccine;

D O I：

10.3390/vaccines10030367

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The Omicron variant of SARS-CoV-2 is emerging in communities where people were previously infected with SARS-CoV-2 and are now being vaccinated, or where many people have received two or three coronavirus vaccination doses. More than 130 countries around the globe have implemented booster dose programs for tackling omicron endemics. Despite early findings shows that booster doses may improve omicron protection, more research is needed to establish vaccination efficacy. This short communication tries to critically discuss the research work findings around booster dose strategy for omicron endemics.

引用

页数：6

共 35 条

[1] Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants [J].

Accorsi, Emma K. ;

Britton, Amadea ;

Fleming-Dutra, Katherine E. ;

Smith, Zachary R. ;

Shang, Nong ;

Derado, Gordana ;

Miller, Joseph ;

Schrag, Stephanie J. ;

Verani, Jennifer R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (07) :639-651

[2]

Bhardwaj S., 2018, VACCINES, V341, P353, DOI [10.1016/B978-0-12-802103-3.00022-5, DOI 10.1016/B978-0-12-802103-3.00022-5]

[3] Omicron variant and booster COVID-19 vaccines [J].

Burki, Talha Khan .

LANCET RESPIRATORY MEDICINE, 2022, 10 (02) :E17-E17

[4]

Chavda P., 2021, Biologics, V1, P337, DOI DOI 10.3390/BIOLOGICS1030020

[5] Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly? [J].

Chavda, Vivek P. ;

Apostolopoulos, Vasso .

MATURITAS, 2022, 158 :78-81

[6] A global picture: therapeutic perspectives for COVID-19 [J].

Chavda, Vivek P. ;

Kapadia, Carron ;

Soni, Shailvi ;

Prajapati, Riddhi ;

Chauhan, Subhash C. ;

Yallapu, Murali M. ;

Apostolopoulos, Vasso .

IMMUNOTHERAPY, 2022, 14 (05) :351-371

[7]

Chavda Vivek P, 2021, Clin Complement Med Pharmacol, V1, P100004, DOI 10.1016/j.ccmp.2021.100004

[8] DNA vaccines for SARS-CoV-2: toward third-generation vaccination era [J].

Chavda, Vivek P. ;

Pandya, Radhika ;

Apostolopoulos, Vasso .

EXPERT REVIEW OF VACCINES, 2021, 20 (12) :1549-1560

[9] Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management [J].

Chavda, Vivek P. ;

Vora, Lalitkumar K. ;

Pandya, Anjali K. ;

Patravale, Vandana B. .

DRUG DISCOVERY TODAY, 2021, 26 (11) :2619-2636

[10] Covid-19: Early studies give hope omicron is milder than other variants [J].

Christie, Bryan .

BMJ-BRITISH MEDICAL JOURNAL, 2021, 375 :n3144

← 1 2 3 4 →